TG Therapeutics (TGTX)
(Delayed Data from NSDQ)
$13.91 USD
-0.07 (-0.50%)
Updated Apr 25, 2024 04:00 PM ET
After-Market: $13.91 0.00 (0.00%) 6:18 PM ET
3-Hold of 5 3
D Value A Growth A Momentum B VGM
Cash flow Statements
Fiscal Year End for TG Therapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | 12.67 | -198.34 | -348.10 | -279.38 | -172.87 |
Depreciation/Amortization & Depletion | 0.56 | 2.03 | 1.88 | 1.05 | 0.62 |
Net Change from Assets/Liabilities | -84.66 | -1.65 | -12.00 | -19.54 | 25.37 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 40.01 | 21.78 | 62.59 | 83.36 | 14.08 |
Net Cash From Operating Activities | -31.41 | -176.17 | -295.63 | -214.51 | -132.81 |
Property & Equipment | 0.00 | -0.01 | -0.40 | -0.36 | -0.13 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | -50.65 | -20.00 | 0.07 | -24.15 | -0.59 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | -50.65 | -20.01 | -0.33 | -24.51 | -0.72 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 47.83 | 0.58 | 2.44 | 679.83 | 175.02 |
Issuance (Repayment) of Debt | 25.00 | -0.98 | 40.00 | 0.00 | 29.99 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | -0.13 | 0.00 | -1.02 | 0.00 | -0.80 |
Net Cash from Financing Activities | 72.71 | -0.39 | 41.42 | 679.83 | 204.21 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | -9.36 | -196.57 | -254.55 | 440.81 | 70.69 |
Cash at Beginning of Period | 103.58 | 300.15 | 554.70 | 113.89 | 43.20 |
Cash at End of Period | 94.22 | 103.58 | 300.15 | 554.70 | 113.89 |
Diluted Net EPS | 0.09 | -1.46 | -2.63 | -2.42 | -1.96 |
Fiscal Year End for TG Therapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | NA | 12.67 | 27.09 | -86.84 | -39.23 |
Depreciation/Amortization & Depletion | NA | 0.56 | 1.37 | 0.82 | 0.28 |
Net Change from Assets/Liabilities | NA | -84.66 | -76.61 | -36.50 | -28.32 |
Net Cash from Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | NA | 40.01 | 29.95 | 20.62 | 7.37 |
Net Cash From Operating Activities | NA | -31.41 | -18.20 | -101.91 | -59.90 |
Property & Equipment | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Acquisition/ Disposition of Subsidiaries | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | NA | -50.65 | -5.90 | 24.33 | -6.17 |
Other Investing Activities | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | NA | -50.65 | -5.90 | 24.33 | -6.17 |
Uses of Funds
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | NA | 47.83 | 47.83 | 47.41 | 0.36 |
Issuance (Repayment) of Debt | NA | 25.00 | 25.00 | 25.00 | 25.00 |
Increase (Decrease) Short-Term Debt | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | NA | -0.13 | -0.13 | -0.13 | -0.13 |
Net Cash from Financing Activities | NA | 72.71 | 72.71 | 72.29 | 25.24 |
Effect of Exchange Rate Changes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | NA | -9.36 | 48.61 | -5.29 | -40.83 |
Cash at Beginning of Period | NA | 103.58 | 103.58 | 103.58 | 103.58 |
Cash at End of Period | NA | 94.22 | 152.18 | 98.29 | 62.75 |
Diluted Net EPS | NA | -0.02 | 0.73 | -0.34 | -0.28 |